MOFFITT CANCER CENTER — History
CCN 100271 | 3-year financial timeline | COVID resilience: 67/100
🛡️ Public data only — no PHI permitted on this instance.
$1.9B
Latest Revenue (FY2022)
+14.9%
Revenue CAGR (3yr)
16.0%
Financial Timeline
| Metric | FY2020 | FY2021 | FY2022 | YoY (Latest) | CAGR |
|---|---|---|---|---|---|
| Net Patient Revenue | $1.4B | $1.7B | $1.9B | +14.5% | +14.9% |
| Operating Expenses | $1.2B | $1.4B | $1.6B | +14.9% | +14.6% |
| Operating Margin | 15.6% | 16.2% | 16.0% | -1.6% | +1.2% |
| Net Income | $226M | $271M | $305M | +12.7% | +16.2% |
| Licensed Beds | 218 | 218 | 218 | +0.0% | +0.0% |
| Total Patient Days | 66,253 | 65,773 | 66,406 | +1.0% | +0.1% |
| Medicare Day % | 32% | 32% | 29% | -9.8% | -5.2% |
| Medicaid Day % | 2% | 1% | 1% | -29.9% | -28.8% |
COVID Impact & Recovery
Resilience Score: 67/100 — Moderate — some COVID impact but recovering
Revenue recovery from FY2020 to FY2022: +32.0% ($1.4B → $1.9B)
FY2020 captured the initial COVID shock. Strong recovery indicates operational resilience and payer diversification.
Trend Summary
Revenue▲ Growing
Operating Margin▲ Growing
Beds▶ Stable
Medicare Mix▲ Growing
vs State Average ()
Revenue Growth
+14.9%
This Hospital
+7.6%
State Avg
Latest Margin
16.0%
This Hospital
-4.6%
State Avg
Projections (FY2023-2025)
Extrapolated from 3-year trend using linear projection. Does not account for regulatory or market changes.
| Year | Revenue (proj) | Margin (proj) |
|---|---|---|
| FY2023 (proj) | $2.1B | 16.2% |
| FY2024 (proj) | $2.4B | 16.4% |
| FY2025 (proj) | $2.6B | 16.5% |